Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CoVac-1 multi-peptide vaccine for COVID-19 prevention
NCT04546841Phase 1Completed
- Sponsor
- University Hospital Tübingen
- Start
- Nov 2020
- Primary completion
- Sep 2021
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CoVac-1 in coronavirus disease 2019 (COVID-19), sponsored by University Hospital Tübingen. Primary endpoints: Eastern Cooperative Oncology Group Status at 28 days, Vital Signs at 28 days and 2 more. Started Nov 2020; status: completed.
02
Drugs
CoVac-1
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04546841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04546841.